Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C

Vaccine

Volumn 27, Issue 37, 2009, Pages 5142-5151

  Wedemeyer, Heiner ^a   Schuller, Elisabeth ^b   Schlaphoff, Verena ^a   Stauber, Rudolf E ^c   Wiegand, Johannes ^d   Schiefke, Ingolf ^d   Firbas, Christa ^e   Jilma, Bernd ^e   Thursz, Mark ^f   Zeuzem, Stefan ^g   Hofmann, Wolf P ^g   Hinrichsen, Holger ^h   Tauber, Erich ^b   Manns, Michael P ^a   Klade, Christoph S ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INTERCELL AG   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Gastroenterology and Hepatology Research   (United Kingdom)

^g SAARLAND UNIVERSITY   (Germany)

^h UNIVERSITY OF KIEL   (Germany)

Author keywords

Hepatitis C virus; IC41; Sustained virologic response

Indexed keywords

HEPATITIS C VACCINE; HEPATITIS C VIRUS PEPTIDE VACCINE IC41; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; MALE; MULTICENTER STUDY; MUSCLE CRAMP; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RELAPSE; RHINOPHARYNGITIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME; VACCINES, SUBUNIT; VIRAL HEPATITIS VACCINES; YOUNG ADULT;

EID: 67650734950     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.027     Document Type: Article

References (47)

1. Moradpour D., Penin F., and Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol 5 6 (2007) 453-463
2. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 9 (2005) 558-567
3. Massard J., Ratziu V., Thabut D., Moussalli J., Lebray P., Benhamou Y., et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 44 (2006) S19-24
4. Fattovich G., and Llovet J.M. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol 44 6 (2006) 1089-1097
5. Leone N., and Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 51 1 (2005) 31-46
6. Klenerman P., and Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 6 9 (2005) 873-879
7. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 3 (2005) 215-229
8. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead-Loudis J., et al. Differential CD4(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33 (2001) 267-276
9. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169 6 (2002) 3447-3458
10. Gruener N.H., Lechner F., Jung M.C., Diepolder H., Gerlach T., Lauer G., et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 75 12 (2001) 5550-5558
11. Lauer G.M., Barnes E., Lucas N., Timm J., Ouchi K., Kim A.Y., et al. High resolution analysis of cellular immune responses and persistent hepatitis C virus infection. Gastroenterology 127 3 (2004) 924-936
12. Neumann-Haefelin C., Timm J., Spangenberg H.C., Wischniowski N., Nazarova N., Kersting N., et al. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 47 6 (2008) 1824-1836
13. Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandi R.T., et al. Broad specificity of virus-specific CD4(+) T-helper-cell responses in resolved hepatitis C virus infection. J Virol 76 (2002) 12584-12595
14. Ciesek S., Liermann H., Hadem J., Greten T., Tillmann H.L., Cornberg M., et al. Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepat 15 3 (2008) 200-211
15. Bain C., Fatmi A., Zoulim F., Zarski J.P., Trepo C., and Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120 (2001) 512-524
16. Sugimoto K., Ikeda F., Stadanlick J., Nunes F.A., Alter H.J., and Chang K.M. Suppression of HCV-specific T-cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38 (2003) 1437-1448
17. Francavilla V., Accapezzato D., De Salvo M., Rawson P., Cosimi O., Lipp M., et al. Subversion of effector CD 8(+) T-cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur J Immunol 24 (2004) 427-437
18. Bowen D.B., and Walker C.M. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 201 11 (2005) 1709-1714
19. Cornberg M., Deterding K., and Manns M.P. Present and future therapy for hepatitis C virus. Expert Rev Anti Infect Ther 4 (2006) 781-793
20. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa 2-a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
21. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 9 (2006) 1350-1359
22. Harris H.E., Eldridge K.P., Harbour S., Alexander G., Teo C.G., Ramsay M.E., and The HCV National Register Steering Group. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?. J Viral Hepat 14 (2007) 213-220
23. Cox A.L., Mosbruger T., Mao Q., Liu Z., Wang X.H., Yangf H.C., et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201 11 (2005) 1741-1752
24. Firbas C., Jilma B., Tauber E., Buerger V., Jelovcan S., Lingnau K., et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 20 (2006) 4343-4353
25. Klade C.S., Wedemeyer H., Berg T., Hinrichsen H., Cholewinska G., Zeuzem S., et al. Therapeutic vaccination of chronic hepatitis C non-responder patients with the peptide vaccine IC41. Gastroenterology 134 (2008) 1385-1395
26. Caetano J., Martinho A., Paiva A., Pais B., Valente C., and Luxo C. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J Virol 82 15 (2008) 7567-7577
27. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N.V., and Hepatitis. C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118 2 (2000) 346-355
28. Wiegand J., Cornberg M., Aslan N., Schlaphoff V., Sarrazin C., Kubitschke A., et al. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. Antivir Ther 12 3 (2007) 303-316
29. Di Puccio T., Pilla L., Capone I., Ferrantini M., Montefiore E., Urbani F., et al. Immunization of stage IV melanoma patients with melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific T cells and monocyte/dentritic cell precursors. Cancer Res 66 9 (2006) 4943-4951
30. Schlaphoff V., Klade C.S., Jilma B., Jelovcan S.B., Cornberg M., Tauber E., et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 25 37-38 (2007) 6793-6806
31. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., and Houghton M. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 6 12 (2007) 991-1000
32. Lauer G.M., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 79 20 (2005) 12979-12988
33. Barnes E., Harcourt G., Brown D., Lucas M., Phillips R., Dusheiko G., et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36 3 (2002) 743-754
34. Pilli M., Zerbini A., Penna A., Orlandini A., Lukasiewicz E., Pawlotsky J.M., et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 133 4 (2007) 1132-1143
35. Kaplan D.E., Sugimoto K., Newton K., Valiga M.E., Ikeda F., Aytaman A., et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132 2 (2007) 654-666
36. Mangia A., Minerva N., Bacca D., Cozzolongo R., Ricci G.L., Carretta V., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 47 1 (2008) 43-50
37. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 4 (2006) 1086-1097
38. Zeuzem S., Pawlotsky J.M., Lukasiewicz E., von Wagner M., Goulis I., Lurie Y., et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 43 2 (2005) 250-257
39. Urbani S., Amadei B., Tola D., Pedrazzi G., Sacchelli L., Cavallo M.C., et al. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 48 4 (2008) 548-558
40. Golden-Mason L., Klarquist J., Wahed A.S., and Rosen H.R. Cutting-edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 180 6 (2008) 3637-3641
41. Golden-Mason L., Palmer B., Klarquist J., Mengshol J.A., Castelblanco N., and Rosen H.R. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81 17 (2007) 9249-9258
42. Penna A., Pilli M., Zerbini A., Orlandini A., Mezzadri S., Sacchelli L., et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45 3 (2007) 588-601
43. Bengsch B., Spangenberg H.C., Kersting N., Neumann-Haefelin C., Panther E., von Weizsäcker F., et al. Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J Virol 81 2 (2007) 945-953
44. Northfield J.W., Kasprowicz V., Lucas M., Kersting N., Bengsch B., Kim A., et al. CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation. Hepatology 47 2 (2008) 396-406
45. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 (2004) 2295-2301
46. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24 (2006) 5461-5472
47. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6 2 (2007) 133-140